Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in: Medical Oncology 1/2011

01-03-2011 | Original Paper

REG gamma: a potential marker in breast cancer and effect on cell cycle and proliferation of breast cancer cell

Authors: Xiaoyi Wang, Shengfen Tu, Jinxiang Tan, Tian Tian, Liang Ran, Jean-Francois Rodier, Guosheng Ren

Published in: Medical Oncology | Issue 1/2011

Login to get access

Abstract

To investigate the expression and significance of proteasomes reactivator REG gamma (γ) in breast cancer. First, we showed the expression of REGγ in breast cancer, metastatic lymph nodes and normal breast tissues. Meanwhile, we also analyzed the relationship between REGγ and estrogen receptor (ER), CerBb-2, lymph nodes metastasis and clinical stage of breast cancer. REGγ expression was determined by immunohistochemical staining and western blot. Secondly, we detected the expression of REGγ and REGγ-mRNA in human breast cancer cell lines (MDA-MB-231, MCF-7) and human breast ductal epithelial cell line (HBL-100) by western blot and real-time PCR. Finally, in order to identify effect of REGγ on breast cancer cell cycle and proliferation, we constructed recombinant plasmid of PcDNA3.1-REGγ and designed siRNA for REGγ in vitro. Cell cycle was assayed by flow cytometer (FCM), proliferation was measured by methyl thiazolyl tetrazolium (MTT). The results demonstrated abnormal high expression of REGγ in breast cancer and its metastatic lymph nodes. REGγ expression was related to breast cancer and its status of ER, CerBb-2 and lymph nodes metastasis. REGγ is one of the potential markers in breast cancer. REGγ could facilitate the growth of breast cancer cells.
Literature
1.
Coux O, Tanaka K, Goldberg AL. Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem. 1996;65:801–47.PubMedCrossRef
2.
Lowe J, Stock D, Jap B, Zwickl P, et al. Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A resolution. Science. 1995;268:533–9.PubMedCrossRef
3.
Ahn K, Erlander M, Leturcq D, Peterson PA, et al. In vivo characterization of the proteasome regulator PA28. J Biol Chem. 1996;271:18237–42.PubMedCrossRef
4.
Soza A, Knuehl C, Groettrup M, Henklein P, et al. Expression and subcellular localization of mouse 20S proteasome activator complex PA28. FEBS Lett. 1997;413:27–34.PubMedCrossRef
5.
Wojcik C, Tanaka K, Paweletz N, Naab U, et al. Proteasome activator (PA28) subunits, α, β and γ (Ki antigen) in NT2 neuronal precursor cells and HeLa S3 cells. Eur J Cell Biol. 1998;77:151–60.PubMed
6.
Rechsteiner M, Realini C, Ustrell V. The proteasome activator 11S REG(PA28) and classIantigen presentation. Biochem J. 2000;345:1–15.PubMedCrossRef
7.
Luscher B, Eisenman RN. c-myc and c-myb protein degradation: effect of metabolic inhibitors and heat shock. Mol Cell Biol. 1998;8:2504–12.
8.
Salvat C, Aquaviva C, Jariel-Encontre I, et al. Are there multiple proteolytic pathways contributing to c-Fos, c-Jun and p53 protein degradation in vivo? Mol Biol Rep. 1999;26:45–51.PubMedCrossRef
9.
He H, Qi XM, Grossmann J, et al. c-Fos degradation by the proteasome. An early, Bcl-2-regulated step in apoptosis. J Biol Chem. 1998;273:25015–9.PubMedCrossRef
10.
Glotzer M, Murry AW, Kirschner MW. Cyclin is degraded by the ubiquitin pathway. Nature. 1991;349:132–8.PubMedCrossRef
11.
Moro A, Perea SE, Pantoja C, et al. IFNα2b induces apoptosis and proteasome-mediated degradation of p27Kip1 in a human lung cancer cell line. Oncol Rep. 2001;8:425–9.PubMed
12.
Machiels BM, Henfling ME, Broers JL, et al. Changes in immunocytochemical detectability of proteasome epitopes depending on cell growth and fixation conditions of lung cancer cell lines. Eur J Cell Biol. 1995;66:282–92.PubMed
13.
Kanayama H, Tanaka K, Aki M, et al. Changes in expressions of proteasome and ubiquitin genes in human renal cancer cells. Cancer Res. 1991;51:6677–85.PubMed
14.
Fan XM, Wong BC, Wang WP, et al. Inhibition of proteasome function induced apoptosis in gastric cancer. Int J Cancer. 2001;93:481–8.PubMedCrossRef
15.
Bold RJ, Virudachalam S, McConkey DJ. Chemosensitization of pancreatic cancer by inhibition of the 26s proteasome. J Surg Res. 2001;100:11–7.PubMedCrossRef
16.
Tenev T, Marani M, McNeish I, et al. Pro-caspase-3 overexpression sensitizes ovarian cancer cells to proteasome inhibitors. Cell Death Differ. 2001;8:256–64.PubMedCrossRef
17.
Kumatori A, Tanaka K, Inamura N, et al. Abnormally high expression of proteasomes in human leukemic cells. Proc Natl Acad Sci USA. 1990;87:7071–5.PubMedCrossRef
18.
Murata S, Kawahara H, Tohma S, et al. Growth retardation in mice lacking the proteasome activator PA28γ. J Biol Chem. 1999;274:38211–5.PubMedCrossRef
19.
Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer. 2001;1:222–31.PubMedCrossRef
20.
Hung CF, Lu KC, Cheng TZ, et al. A novel siRNA validation system for functional screening and identification of effective RNAi probes in mammalian cells. Biochem Biophys Res Commun. 2006;346(3):707–20.PubMedCrossRef
21.
Masson P, Andersson O, Petersen UM, et al. Identification and characterization of a Drosophila nuclear proteasome regulator. A homolog of human 11 S REGγ(PA28γ). J Biol Chem. 2001;276:1383–90.PubMedCrossRef
22.
Gao X, Li J, Pratt G, et al. Purification procedures determine the proteasome activation properties of REG gamma (PA28 gamma). Arch Biochem Biophys. 2004;425:158–64.PubMedCrossRef
23.
Tomohisa O, Shin-Ichi T, Tsuyoshi O, et al. Abnormally high expression of proteasome activator-γin Thyroid neoplasm. J Clin Endocrinol Metab. 2003;88:1374–83.CrossRef
24.
Chen X, Barton LF, Chi Y, et al. Ubiquitin-independent degradation of cell-cycle inhibitors by the REG gamma proteasome. Mol Cell. 2007;26:843–52.PubMedCrossRef
25.
Yi T, Baek JH, Kim HJ, et al. Trichostatin A-mediated upregulation of p21(WAF1) contributes to osteoclast apoptosis. Exp Mol Med. 2007;39:213–21.PubMed
26.
Lee CJ, Kim HT, et al. Ovarian expression of p53 and p21 apoptosis regulators in gamma-irradiated mice. Mol Reprod Dev. 2008;75:383–91.PubMedCrossRef
27.
Bianchi S, Paglierani M, Zampi G, et al. Prognostic value of proliferating cell nuclear antigen in lymph node-negative breast cancer patients. Cancer. 1993;72:120–5.PubMedCrossRef
28.
Clark GM, Sledge GW, Osborne CK, et al. Survival from first recurrence: relative importance of prognostic factors in 1015 breast cancer patients. J Clin Oncol. 1987;5:55–61.PubMed
29.
Thompson DA, Weigel RJ. Characterization of a gene that is inversely correlated with oestrogen receptor expression (ICERE-1) in breast carcinomas. Eur J Biochem. 1998;252:169–77.PubMedCrossRef
30.
Platet N, Prevostel C, Derocq D, et al. Breast cancer cell invasiveness: correlation with protein kinase C activity and differential regulation by phorbol ester in oestrogen receptor-positive and -negative cells. Int J Cancer. 1998;75:750–6.PubMedCrossRef
31.
Pluciennik E, Kusinska R, Potemski P, et al. WWOX—the FRA16D cancer gene: expression correlation with breast cancer progression and prognosis. Eur J Surg Oncol. 2006;32:153–7.PubMedCrossRef
32.
Tagliabue E, Menard S, Robertson JF, et al. c-erbB-2 expression in primary breast cancer. Int J Biol Markers. 1999;14:16–26.PubMed
33.
Shunqian J, Qimin Z. Oncomolecularbiology is the forefront of basic medical research. World Chin J Dig. 2002;10:678–80.
Metadata
Title
REG gamma: a potential marker in breast cancer and effect on cell cycle and proliferation of breast cancer cell
Authors
Xiaoyi Wang
Shengfen Tu
Jinxiang Tan
Tian Tian
Liang Ran
Jean-Francois Rodier
Guosheng Ren
Publication date
01-03-2011
Publisher
Springer US
Published in
Medical Oncology / Issue 1/2011
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-010-9546-8

Other articles of this Issue 1/2011

Medical Oncology 1/2011 Go to the issue

Original Paper

Prognostic evaluation of immunohistochemical profiles in diffuse large B-cell lymphoma: a Chinese study

Original Paper

Randomized, double-blind, crossover study of palonosetron compared with granisetron for the prevention of chemotherapy-induced nausea and vomiting in a Chinese population

Original Paper

Successful treatment of gefitinib-induced acute interstitial pneumonitis with high-dose corticosteroid: a case report and literature review

Original Paper

Expression of indoleamine 2,3-dioxygenase in acute myeloid leukemia and the effect of its inhibition on cultured leukemia blast cells

Original Paper

Overexpression of c-erbB-2 and loss of p16 have molecular diagnostic relevance but no prognostic value in lung cancer

Original Paper

Clinical significance of the ratio between the alpha 2 plasmin inhibitor–plasmin complex and the thrombin–antithrombin complex in advanced non-small cell lung cancer
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits